Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
M.E. Molitch.
Pathologic hyperprolactinemia.
Endocrinol Metab Clin North Am, 21 (1992), pp. 877-901
[2.]
S.R. Kelley, T.J. Kamal, M.E. Molitch.
Mechanism of verapamil calcium channel blockade induced hyperprolactinemia.
Am J Physiol, 270 (1996), pp. 96-100
[3.]
R.C. Dombrowski, J.H. Romeo, D.C. Aron.
Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma.
Ann Pharmacother, 29 (1995), pp. 999-1001
[4.]
J.H. Romeo, R. Dombrowski, Y.S. Kwak, S. Fuehrer, D.C. Aron.
Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men.
Clin Endocrinol Oxf, 45 (1996), pp. 571-575
[5.]
M. Knoepfelmacher, S.M. Villares, W. Nicolau, O.O. Germek, A.C. Lerario, B.L. Wajchenberg, et al.
Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia.
Horm Metab Res, 26 (1994), pp. 481-485
[6.]
D. Barbaro, F. Faggionato, S. Pallini, C. Carnesecchi, A. Palla, M. Bombara, et al.
Verapamil acute administration: a new dynamic test in hyperprolactinemic states.
Metabolism, 48 (1999), pp. 1351-1356
[7.]
T. Lockett.
Evidence-based and costeffective medicine for the uninitiated.
Copyright © 2000. Elsevier España, S.L.. Todos los derechos reservados
